Doxorubicin hydrochloride and cyclophosphamide followed by tamoxifen, versus the combination of gonadotropin-releasing hormone analog and tamoxifen, in the treatment of premenopausal endocrine-responsive node-negative breast cancer.

Abstract

e11090 Background: The objective of this study is to report our experience of gonadotropin-releasing hormone analog plus tamoxifen (GnRHa+T) or doxorubicin hydrochloride and cyclophosphamide (AC) followed by tamoxifen (AC->T) in premenopausal women with hormone response, node negative breast cancer. Methods: We retrospectively reviewed the records of 587 premenopausal women with hormone- responsive, node-negative breast cancer. Of these, 269 were treated with doxorubicin hydrochloride and cyclophosphamide (AC) followed by tamoxifen (AC->T), and 318 were treated with gonadotropin-releasing hormone analog plus tamoxifen (GnRHa+T). Results: At a median follow-up time of 49 months, 25 patients had relapsed and 6 patients had died. Of the 6 deaths, 3 were related to breast cancer. DFS and OS did not differ between the AC->T and GnRHa+T groups. There were no difference of time to recurrence and death between two groups. Type of recurrence did not differ between the two groups. GnRHa+T treatment had no effect on blood profile and did not cause the development of detrimental symptoms but decreased bone mineral density. Conclusions: GnRHa +T treatment can be an alternative treatment option in pre-menopausal women with endocrine-responsive, node- negative, breast cancer patients. No significant financial relationships to disclose.